Lic. Jorge Romero S. - Academia.edu (original) (raw)

Uploads

Papers by Lic. Jorge Romero S.

Research paper thumbnail of Metaphylactic effect of Diclazuril 0.25% in suckling beef calves, during a coccidiosis outbreak in extensive farming

Veterinary Parasitology, 2013

The weight gain performance and oocysts reduction, as response to the metaphylactic treatment wit... more The weight gain performance and oocysts reduction, as response to the metaphylactic treatment with Diclazuril 0.25% at the start of a coccidiosis outbreak, was studied by a cases-controls transverse study. Fifty-eight suckling calves of approximately 90 days old were randomly selected from an infected beef herd on extensive farming. The calves were weighted and individual faecal samples were taken for oocyst per gram count (OPG). Out of those, 29 were drenched with 1 mg kg −1 of Diclazuril in one oral dose (group T), since the other 29 remained as control group (group C). Samples for OPG and weights were measured again at days 7 and 21 after treatment, respectively. Later, the groups were divided (by the median) in higher or lower OPG counts, and were compared in the same way, in order to remove those without apparent infection (lower OPG counts). The faecal oocysts reduction reached 99.5% (p < 0.0001), for the treated group. Along the three weeks of study, an increment of 2.65 kg in 21 days (125 g day −1 , p = 0.036), was seen in treated group respect to controls, but this difference increased to 3.94 kg in 21 days (p < 0.0001), when only the calves with higher OPG were taken into account. These results highlight the magnitude of the subclinical impact of coccidiosis, biased by the individual susceptibility to infection, which leads to get heavier infections and express higher oocysts output.

Research paper thumbnail of Efecto de la polaridad en la termólisis del diperóxido cíclico de acetona en solución. Cinética en octanol

unne.edu.ar

... 9-Cañizo, AI “Efecto de solvente en la descomposición térmica de Triperoxido Cíclico de Dieti... more ... 9-Cañizo, AI “Efecto de solvente en la descomposición térmica de Triperoxido Cíclico de Dietilcetona (3,3,6,6,9,9-hexaetil-1,2,4,5 ... 11-Leiva, Laura C. - Jorge, Nelly L. - Cafferata, Lázaro F. - Gómez Vara, Manuel E. Comunicaciones Científicas y Tecnoló-gicas (UNNE), Sección ...

Research paper thumbnail of Meta-Analysis of Randomized Trials of Angioedema as an Adverse Event of Renin–Angiotensin System Inhibitors

The American Journal of Cardiology, 2012

Angioedema is a rare, potentially life-threatening adverse event of renin-angiotensin system inhi... more Angioedema is a rare, potentially life-threatening adverse event of renin-angiotensin system inhibitors. The objective of the present study was to determine the risk of angioedema from randomized clinical trials. A PubMed/CENTRAL/EMBASE search was made for randomized clinical trials from 1980 to October 2011 in patients on angiotensinconverting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or direct renin inhibitor (DRI). Trials with a total number of patients >100 and a duration of >8 weeks were included for analysis. Incidence of angioedema was pooled by weighing the incident rate of each trial by the inverse of the variance. Twenty-six trials with 74,857 patients in the ACE inhibitor arm with 232,523 person-years of follow-up, 19 trials with 35,479 patients on ARB with 122,293 person-years of follow-up, and 2 trials with 5,141 patients on DRI with 1,735 person-years of follow-up met the inclusion criteria and were included in the analysis. In head-to-head comparison in 7 trials, risk of angioedema with ACE inhibitors was 2.2 times higher than with ARBs (95% confidence interval [CI] 1.5 to 3.3). With ACE inhibitors and ARBs, incidence of angioedema was higher in heart failure trials compared to hypertension or coronary artery disease trials without heart failure (p <0.0001). Weighted incidence of angioedema with ACE inhibitors was 0.30% (95% CI 0.28 to 0.32) compared to 0.11% (95% CI 0.09 to 0.13) with ARBs, 0.13% (95% CI 0.08 to 0.19) with DRIs, and 0.07% with placebo (95% CI 0.05 to 0.09). In conclusion, incidence of angioedema with ARBs and DRI was <1/2 than that with ACE inhibitors and not significantly different from placebo. Incidence of angioedema was higher in patients with heart failure compared to those without heart failure with ACE inhibitors and ARBs.

Research paper thumbnail of Metaphylactic effect of Diclazuril 0.25% in suckling beef calves, during a coccidiosis outbreak in extensive farming

Veterinary Parasitology, 2013

The weight gain performance and oocysts reduction, as response to the metaphylactic treatment wit... more The weight gain performance and oocysts reduction, as response to the metaphylactic treatment with Diclazuril 0.25% at the start of a coccidiosis outbreak, was studied by a cases-controls transverse study. Fifty-eight suckling calves of approximately 90 days old were randomly selected from an infected beef herd on extensive farming. The calves were weighted and individual faecal samples were taken for oocyst per gram count (OPG). Out of those, 29 were drenched with 1 mg kg −1 of Diclazuril in one oral dose (group T), since the other 29 remained as control group (group C). Samples for OPG and weights were measured again at days 7 and 21 after treatment, respectively. Later, the groups were divided (by the median) in higher or lower OPG counts, and were compared in the same way, in order to remove those without apparent infection (lower OPG counts). The faecal oocysts reduction reached 99.5% (p < 0.0001), for the treated group. Along the three weeks of study, an increment of 2.65 kg in 21 days (125 g day −1 , p = 0.036), was seen in treated group respect to controls, but this difference increased to 3.94 kg in 21 days (p < 0.0001), when only the calves with higher OPG were taken into account. These results highlight the magnitude of the subclinical impact of coccidiosis, biased by the individual susceptibility to infection, which leads to get heavier infections and express higher oocysts output.

Research paper thumbnail of Efecto de la polaridad en la termólisis del diperóxido cíclico de acetona en solución. Cinética en octanol

unne.edu.ar

... 9-Cañizo, AI “Efecto de solvente en la descomposición térmica de Triperoxido Cíclico de Dieti... more ... 9-Cañizo, AI “Efecto de solvente en la descomposición térmica de Triperoxido Cíclico de Dietilcetona (3,3,6,6,9,9-hexaetil-1,2,4,5 ... 11-Leiva, Laura C. - Jorge, Nelly L. - Cafferata, Lázaro F. - Gómez Vara, Manuel E. Comunicaciones Científicas y Tecnoló-gicas (UNNE), Sección ...

Research paper thumbnail of Meta-Analysis of Randomized Trials of Angioedema as an Adverse Event of Renin–Angiotensin System Inhibitors

The American Journal of Cardiology, 2012

Angioedema is a rare, potentially life-threatening adverse event of renin-angiotensin system inhi... more Angioedema is a rare, potentially life-threatening adverse event of renin-angiotensin system inhibitors. The objective of the present study was to determine the risk of angioedema from randomized clinical trials. A PubMed/CENTRAL/EMBASE search was made for randomized clinical trials from 1980 to October 2011 in patients on angiotensinconverting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or direct renin inhibitor (DRI). Trials with a total number of patients >100 and a duration of >8 weeks were included for analysis. Incidence of angioedema was pooled by weighing the incident rate of each trial by the inverse of the variance. Twenty-six trials with 74,857 patients in the ACE inhibitor arm with 232,523 person-years of follow-up, 19 trials with 35,479 patients on ARB with 122,293 person-years of follow-up, and 2 trials with 5,141 patients on DRI with 1,735 person-years of follow-up met the inclusion criteria and were included in the analysis. In head-to-head comparison in 7 trials, risk of angioedema with ACE inhibitors was 2.2 times higher than with ARBs (95% confidence interval [CI] 1.5 to 3.3). With ACE inhibitors and ARBs, incidence of angioedema was higher in heart failure trials compared to hypertension or coronary artery disease trials without heart failure (p <0.0001). Weighted incidence of angioedema with ACE inhibitors was 0.30% (95% CI 0.28 to 0.32) compared to 0.11% (95% CI 0.09 to 0.13) with ARBs, 0.13% (95% CI 0.08 to 0.19) with DRIs, and 0.07% with placebo (95% CI 0.05 to 0.09). In conclusion, incidence of angioedema with ARBs and DRI was <1/2 than that with ACE inhibitors and not significantly different from placebo. Incidence of angioedema was higher in patients with heart failure compared to those without heart failure with ACE inhibitors and ARBs.